Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.585 -0.105 (-3.90%)
Streaming Delayed Price Updated: 1:30 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,535
Open 2.565
Bid (Size) 2.570 (2)
Ask (Size) 2.600 (1)
Prev. Close 2.690
Today's Range 2.420 - 2.659
52wk Range 1.100 - 6.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition
Via Investor Brand Network
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Wall Street Conference on May 21
Via Investor Brand Network
Exposures Product Safety

Performance

YTD
-13.5%
-13.5%
1 Month
+35.3%
+35.3%
3 Month
+5.5%
+5.5%
6 Month
+110.2%
+110.2%
1 Year
-33.7%
-33.7%

More News

Read More
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
Via Investor Brand Network
Exposures Product Safety
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
$7.8 Million in New Financing for Clinic Acquisitions Supporting Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression and PTSD: NRXP
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy
Via Investor Brand Network
Exposures Product Safety
Earnings Scheduled For May 15, 2025
Via Benzinga
PsychedelicNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Uncovering Potential: NRX Pharmaceuticals's Earnings Preview
Via Benzinga
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q1 2025 Results on May 15
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter
Via Stocktwits
Topics Intellectual Property Law Enforcement Lawsuit
Exposures Financial Intellectual Property Legal
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100
Via Investor Brand Network
Exposures Product Safety
$4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Promising Treatment Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD with Groundbreaking Drugs and Modalities: $NRXP
Via Get News
Exposures Product Safety
$300 Million in Milestones; Double-Digit Royalties; LOI with Neurospa for Expansion of International Psychiatry Clinics; NDA Filed with FDA on New Drug: NRx Pharmaceuticals: (Stock Symbol: NRXP)
Via Get News
Exposures Product Safety
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding
Via Stocktwits
What's Going On With NRX Pharmaceuticals Stock Tuesday?
Via Benzinga

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.585
When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 05/23/25 01:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.